logo
‘A mere virus': Perth family's heartbreaking plea after losing daughter, 2, to the flu

‘A mere virus': Perth family's heartbreaking plea after losing daughter, 2, to the flu

News.com.au29-07-2025
A Perth family has issued an emotional plea after their two-year-old daughter died from the flu.
In a letter shared by the Immunisation Foundation of Australia, the heartbroken family described how the health of their two-year-old daughter, Aabi, rapidly deteriorated from the virus.
Only a few months away from turning three, Aabi and her family had returned to their home in Perth on April 30 after spending a month abroad in India visiting relatives.
Aabi's parents said she was 'reluctant' to return to daycare, but was sent back the next day.
It was only a few days later that Aabi vomited after eating her regular banana and milk.
'I initially thought it was due to her energetic play with her sister,' her mother wrote.
'As I cleaned her, I noticed she felt lukewarm.'
The two-year-old complained of a headache, with her mother giving her a dose of paracetamol syrup and a 'gentle forehead massage' that seemed to help.
While Aabi's mood seemed to improve, her fever - and the niggling headache - returned a short time later.
'(On) Sunday, May 4th, she woke as usual - enjoying two biscuits with my tea, her milk, and then a banana,' her mother wrote.
'She was playing, singing, and seemed well.
'Relieved, I started my regular Sunday household tasks while the girls entertained themselves.'
However by about 11am that morning, Aabi's temperature was rising again and her headache had returned.
'I sat beside her, waiting for the fever to drop, but it kept climbing,' her mother wrote.
Aabi's fever kept climbing to 40.6C and she was rushed to hospital, where her dehydration made it difficult for doctors to figure out the problem.
'It felt like she deteriorated significantly and too quickly,' her mother said.
Aabi had a 'gentle seizure' while in hospital and was later diagnosed with influenza.
'The decision was made to perform a CT scan and then transfer her to the ICU, as she was highly febrile and partially unconscious,' the letter read.
However, the little girl's health had deteriorated too quickly for the CT scan to be effective and she instead required an MRI scan.
Aabi's mum said it was then she believed they had lost their little girl, saying her pupils were non-responsive and 'she was beyond anyone's help'.
In the span of a few days, Aabi had gone from being a 'healthy, happy, active, and fun-loving child' to lying unconscious in the hospital bed.
The MRI scan confirmed the worst.
'The MRI confirmed total brain death due to acute necrotising encephalitis, a devastating complication of the influenza infection,' her mother wrote.
'The virus's rapid progression with such minimal initial symptoms – just a normal fever and headache, which so many children her age experience regularly – gave us no indication of the extreme seriousness of the situation.'
Aabi's mother said doctors suspect her daughter's immune system reacted 'much more aggressively than usual', which led to 'acute inflammation and severe damage to her brain'.
'We lost our beautiful Aabi at the hands of what seemed like a 'mere virus',' she said.
'Aabi will forever be two years and nine months old,' her mother wrote, describing her daughter as the 'radiant joy of our lives and the very heart of our home'.
Flu spike 'really concerning'
Immunisation Foundation of Australia founder Catherine Hughes said Aabi's story was a reminder of the tragic impact influenza can have, and highlights just how vulnerable young children are to infectious diseases.
She said an ongoing spread of misinformation was leading to shockingly low rates of flu vaccination, something she described as a 'serious public health concern'.
According to figures from the National Centre for Immunisation Research and Surveillance (NCRIS), more than 230,000 lab-confirmed flu cases have been reported in the country as of late July.
Less than a quarter of those cases are children under the age of five.
Ms Hughes said the numbers were 'really concerning'.
'Many of us might mistakenly think of the flu as 'just a bad cold', especially after a mild case,' she told NewsWire.
'However, influenza can be extremely severe, leading to serious complications, hospitalisation, and death, even for healthy children and adults.'
This could be reduced with higher vaccination rates, she said.
'We urge families to prioritise vaccination as a proactive step to protect their children, prevent the wider spread of the virus, and ultimately, help protect all Australians,' she told NewsWire.
Monash University Epidemiological Modelling Unit for the School of Public Health and Preventive Medicine associate professor James Trauer reiterated it was important for Australians to get vaccinated against the flu.
He told NewsWire the flu vaccine presented 'little chemicals to the immune system' that are in both the vaccine and flu virus, meaning the body is exposed to the chemicals without the body having to be exposed to the flu virus itself.
'So you develop antibodies … once you've got those antibodies, you have a more effective, more rapid response to the vaccine,' he said.
He said children under five and the population over 65 were the biggest priority for flu vaccinations, though the general public - particularly those with young children - should also get the jab.
'The flu transmits a lot within family units,' he said.
'(The) flu causes a major epidemic every winter, and people do die of it every year, and so it's important for us to do everything that we can (to prevent it).'
While there are 'some other treatments' to prevent the virus, he said 'vaccination is really the best … preventive and effective intervention' that can 'really help us to reduce the flu each winter'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Valentina is the first Australian ever with extremely rare genetic condition
Valentina is the first Australian ever with extremely rare genetic condition

News.com.au

time3 hours ago

  • News.com.au

Valentina is the first Australian ever with extremely rare genetic condition

Valentina's face lights up when customers enter her mum and dad's sandwich shop in Sydney's Little Italy. 'We call her the welcoming party. She sits there and smiles at people when they come in. She's done that from day one,' says Valentina's mum Sara. You would never know that every day is a struggle for the 14-month-old who has a condition so rare she is the only Australian in history to receive her diagnosis. Less than 200 people on the planet have ever experienced what she is experiencing — a rare genetic abnormality that was the result of the ever rarer circumstance that both her parents carried the same gene. 'That we would both have it and marry each other and have a child was so unlikely,' Sara says. 'There are 200 of these cases, ever in the world. None in Australia. Usually these people are cousins who have the same gene but that's not the case with us. So it's pretty crazy that this has manifested this way.' Valentina has Hyaline Fibromatosis Sydrome, characterised by severe pain with movement and progressive joint contractures. 'She can't stretch her legs or lift her arms above her head,' Sara tells 'It manifests through gut problems too, where you don't hold in the nutrients from foods, face rashes, things like that.' Getting a diagnosis was a miracle in itself, one that started the day after she was born when Sara's instincts told her something was not right. 'It was the second day after coming out of the c-section. I noticed straight away,' she says. 'I am an overthinker, but everyone was like, 'you're trying to find a problem'. But I knew.' Sara says she was 'robbed' of the first four months of Valentina's life trying to get somebody to listen and acknowledge what she knew deep down. 'I went to a check-up with the community nurse after we left hospital and she agreed that she wasn't moving her arms properly. 'We went for a brain scan and it came up as nothing. Her brain is unaffected.' Despite receiving no diagnosis, Sara started taking Valentina to physio from four weeks old. 'I kept going as if something was wrong even though nobody would confirm it. A pediatrician at three months said 'yep, actually her legs are concerning me the most'. Her legs had gone from completely normal to completely contracted. 'We went to the hospital on October 9 last year and they were searching and searching and searching for the gene that was causing the problem. 'It is very very difficult to find because our mutations of this gene have never been reported.' Valentina became a research patient. Her DNA and genetics were sent to researchers in Perth who found the gene and checked it against Sara and her husband Dom. 'They confirmed we both had these mutations. Initially they told us we might never have a diagnosis. They said it could take five weeks or five years but we got it in three months.' That's step one. The next step is a bit unknown. 'For us, we're writing the book for this,' Sara says. 'So we don't know the prognosis. We are absolutely writing the book. 'All I know is that she's getting better. There are situations where the contractions can stabilise so we're hoping that's what happens. We don't know the outcome after that. She is on her feet standing with splints. 'When people ask me, 'is she going to walk?'. I say 'I don't know, your guess is as good as mine'. There are no case studies for us to follow, we take it day by day really.' The family's sandwich shop, Dom Panino, sits on the corner of Marion and Edith streets in Leichardt, the iconic inner west suburb of Sydney best known for its Italian food and culture. It started as a food truck at Breakfast Point before Dom and Sara found the perfect location — a restaurant Dom used to frequent when he was younger with his family. Valentina sits inside the entrance now welcoming customers with a smile. In a heartwarming video posted to the pair's social media pages, customers rallied around the family. 'This panino is for Valentina and Jeans for Genes,' customers recited on a day that raised more than $24,000 for the Children's Medical Research Institute. Jeans for Genes Day, which takes place this Thursday, August 7, is about finding treatments for the one-in-20 Aussie children like Valentina who live with conditions like cancer, cystic fibrosis and other devastating genetic diseases. The cause helps raise money to keep labs open, continue with life-changing science and save lives. Sara says raising funds and speaking up for her little girl are an important way of helping her move through the grief. 'This can't be for nothing,' she says. 'I can't just sit here and not tell the world about it. I want Valentina to know that she's so incredible, and so brave and so strong and she's going to live a normal life. I want to make a difference.'

MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks

News.com.au

time5 hours ago

  • News.com.au

MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks

MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.

Family grateful for end-of-life care at Rockhampton's Fitzroy Community Hospice
Family grateful for end-of-life care at Rockhampton's Fitzroy Community Hospice

ABC News

time5 hours ago

  • ABC News

Family grateful for end-of-life care at Rockhampton's Fitzroy Community Hospice

Struggling to breathe, battling a staphylococcus infection and suffering from other age-related illnesses, Neil Robinson's family knew he was nearing the end of his life. His family did not want the 85-year-old to die in hospital, but knew bringing him home could be overwhelming and complicated. "His ailments were complex, and it was very daunting to think about caring for him ourselves," Neil's daughter-in-law Toni Robinson said. A friend suggested hospice care, and it ended up being the solution Neil's family was looking for. "My friend's father was cared for at a hospice, and it was such a comfort to his family," she said. Neil spent his last week at the Fitzroy Community Hospice, the only end-of-life care option outside hospitals or aged care homes between Gympie and Townsville, a stretch of nearly 1,000 kilometres. The community not-for-profit hospice opened its doors in June 2024 to provide better end-of-life care in central Queensland. The second stage of the project opened last month to expand its capacity. The new rooms have more space for families, which means people coming from outside the area to be with loved ones have somewhere to stay. "Some people have confused us with aged care, but those we care for are referred to us through medical practitioners and nurse practitioners," chief executive officer Beth Thomas said. Funding is provided through an agreement with Queensland Health for several public beds and private health insurers, as well as ongoing fundraising. Ms Thomas said the organisation's executives worked with local GPs and the community to get the word out about the specifics of end-of-life care. "It's about taking the burden of care from families and hospitals," Ms Thomas said. "A big difference from a hospital is that we don't have fixed visiting hours. Family members and pets can come and visit any time. "It is meant to be a soothing and calming environment with no bells and whistles and bustling that the hospital has." Allison Leech, a nursing teacher at CQ University and former director of nursing at Toowoomba Hospice, believed more palliative care options were needed in regional areas as it eases the burden for both local health care systems and families. "Many Australians want to die at home, but it's not always possible. So this becomes a home-like environment, and patients and families can do things on their own terms." Fitzroy Hospice clinical nurse Megan Anderson saw the hospice as a place to create memories. "It is holistic and we see the family as a key part of patient care," she said. A Queensland Health spokesperson said hospice care was a critical part of the health care system, providing funding to some non-government organisations for palliative care services. "Our palliative and end-of-life care strategy includes $171 million to fund more palliative care services and boost the workforce across the state," the spokesperson said. Neil died in January this year after spending a week at the hospice. Ms Robinson said the week was spent sitting at Neil's side with Hope, the family dog, resting her head in Neil's hand. She said it was a "peaceful passing for Neil" and a comforting experience for the family. "The staff provided us with everything we needed to know so we understood the dying process," Ms Robinson said. "It was the next best thing to caring for Neil at home."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store